466 related articles for article (PubMed ID: 18413802)
21. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
23. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Fecteau JF; Bharati IS; O'Hayre M; Handel TM; Kipps TJ; Messmer D
Mol Med; 2012 Feb; 18(1):19-28. PubMed ID: 21979753
[TBL] [Abstract][Full Text] [Related]
25. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
[TBL] [Abstract][Full Text] [Related]
26. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
27. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
28. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
31. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
34. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
[TBL] [Abstract][Full Text] [Related]
35. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
Gysin S; Lee SH; Dean NM; McMahon M
Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
[TBL] [Abstract][Full Text] [Related]
36. The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Heim M; Scharifi M; Zisowsky J; Jaehde U; Voliotis D; Seeber S; Strumberg D
Anticancer Drugs; 2005 Feb; 16(2):129-36. PubMed ID: 15655409
[TBL] [Abstract][Full Text] [Related]
37. Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Matsuzawa Y; Kiuchi Y; Toyomura K; Matsumoto I; Nakamura H; Fujino H; Murayama T; Kawashima T
J Pharmacol Sci; 2009 Oct; 111(2):182-92. PubMed ID: 19783865
[TBL] [Abstract][Full Text] [Related]
38. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
[TBL] [Abstract][Full Text] [Related]
40. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.
Park JI; Strock CJ; Ball DW; Nelkin BD
Mol Cell Biol; 2003 Jan; 23(2):543-54. PubMed ID: 12509453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
